About Mass General Neurotherapeutics
Mass General Neurotherapeutics is a vibrant community of investigators and clinical researchers, developing cutting-edge, breakthrough therapies for the most challenging and devasting neurological and psychiatric disorders. We take on the greatest challenges – in close partnership with our patients and in collaboration with our many partners across Mass General and the scientific community - making discoveries and effectively translating them into therapies for patients. Our multi-disciplinary approach combines the highest level of patient care with Mass General’s world class neurotherapeutics research endeavors and facilities.
I look forward to coming in every two weeks for my infusion because I get to spend time with some really smart, incredibly caring people."
Trial Participant (sample quote-he is an EAP participant so we would need a clinical trial participant to speak with)
We are relentless in our mission to hasten drug discoveries to meet the needs of patients everywhere suffering from debilitating neurological and psychiatric disorders.
Below, you will find links to current clinical trials and educational material to better understand neurological and psychiatric medical issues, as well as information about our latest neurotherapeutic breakthroughs, research and clinical advances.
We focus on modern and emerging therapies including electroconvulsive therpay (ECT), vagus nerve stimulation (VNS) and functional neurosurgery.
Are you planning on receiving ECT treatments for depression? Are you interested in getting an MRI scan of your brain? If you answered yes, you may be eligible for our study.
Investigating a novel treatment for bipolar depression in older adults aged 55 and older.
- ALS Patient Education
- Diagnosing ALS
- About Electromyography (EMG) Tests
- Transcranial Magnetic Stimulation (TMS) Clinical Service
- CAR T-Cell Therapies
Multi-Departamental Epilepsy Initiative (site in progress)
Advances in Neurotherapeutics
Read our latest neurotherapeutic breakthroughs, research and clinical advances.